Volume 31, Number 4—April 2025
Synopsis
Alistipes Bacteremia in Older Patients with Digestive and Cancer Comorbidities, Japan, 2016–2023
Naoki Watanabe
, Tomohisa Watari, Naoto Hosokawa, and Yoshihito Otsuka
, Tomohisa Watari, Naoto Hosokawa, and Yoshihito Otsuka
Table 1
Demographic and clinical characteristics of patients with Alistipes bacteremia in a tertiary care center in Japan, 2016–2023*
| Characteristics | All, n = 13 | Alive, n = 11 | Death, n = 2 |
|---|---|---|---|
| Age | |||
| Median, y (IQR) | 72 (65–85) | 70 (59–85) | 80 (78–83) |
| >65 y |
10 (76.9) |
8 (72.7) |
2 (100.0) |
| Sex | |||
| F | 7 (53.8) | 6 (54.5) | 1 (50.0) |
| M |
6 (46.2) |
5 (45.5) |
1 (50.0) |
| Site of acquisition | |||
| Community | 7 (53.8) | 7 (63.6) | 0 |
| Healthcare-associated |
6 (46.2) |
4 (36.4) |
2 (100.0) |
| Charlson Comorbidity Index score | |||
| 0 | 4 (30.8) | 4 (36.4) | 0 |
| 1–2 | 4 (30.8) | 3 (27.3) | 1 (50.0) |
| 3–4 | 2 (15.4) | 2 (18.2) | 0 |
| >5 |
3 (23.1) |
2 (18.2) |
1 (50.0) |
| Comorbid conditions | |||
| Solid tumor | 6 (46.2) | 4 (36.4) | 2 (100.0) |
| Hematologic malignancies | 1 (7.7) | 1 (9.1) | 0 |
| Leukopenia | 2 (15.4) | 2 (18.2) | 0 |
| Chemotherapy | 3 (23.1) | 3 (27.3) | 0 |
| Immunosuppressive therapy | 0 | 0 (0.0) | 0 |
| Intravascular device |
3 (23.1) |
2 (18.2) |
1 (50.0) |
| Symptoms | |||
| Abdominal pain | 9 (69.2) | 8 (72.7) | 1 (50.0) |
| Diarrhea | 1 (7.7) | 1 (9.1) | 0 |
| Sepsis or septic shock | 3 (23.1) | 1 (9.1) | 2 (100.0) |
| Fever | 6 (46.2) | 6 (54.5) | 0 |
| Vomiting |
3 (23.1) |
3 (27.3) |
0 |
| Time to positivity, h (IQR) | 81 (71–106) | 76 (68–103) | 94 (88–99) |
*Values are no. (%) except as indicated. IQR, interquartile range.
Page created: February 18, 2025
Page updated: March 24, 2025
Page reviewed: March 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.